NCT00525954View on ClinicalTrials.gov

PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

September 30, 2007

Study Completion Date

December 31, 2007

Conditions
Coronary Artery Disease
Interventions
DRUG

A-002

Trial Locations (13)

13210

Cardiology PC, Syracuse

13901

United Medical Associates, Binghamton

23507

Clinical Research Associates of Tidewater, Norfolk

30901

Augusta Cardiology Clinic, Augusta

33609

Florida Cardiovascular Research Institute, Tampa

33952

Charlotte Cardiovascular Institute, Port Charlotte

34667

Pasco Cardiology Center, Hudson

36608

Mobile Heart Specialists, Mobile

40207

Louisville Cardiology Medical Group, Louisville

53715

Wisconsin Heart, SC, Madison

78705

Austin Heart, Austin

85260

Sonoran Health Specialists, Scottsdale

04210

Maine Research Associates, Auburn

Sponsors
All Listed Sponsors
lead

Anthera Pharmaceuticals

INDUSTRY

NCT00525954 - PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease | Biotech Hunter | Biotech Hunter